E100 Patient perspectives on treatment satisfaction and unmet needs in rheumatoid arthritis - results from a national UK survey

Background/Aims Despite substantial therapeutic advances, rheumatoid arthritis (RA) continues to impose a high burden on patients. To better understand current patient experiences, treatment satisfaction, and unmet needs, AnaptysBio partnered with the National Rheumatoid Arthritis Society (NRAS) in the United Kingdom to conduct a national survey of individuals living with RA. Methods A 15-question survey was administered by NRAS via social media and e-newsletters between 16 June and 21 July 2025 through the Sogolytics survey platform. The survey collected demographic data, patient perspectives on treatment satisfaction, frequency of flares, and the broader impact of RA on quality of life. Descriptive analyses were performed. Results A total of 874 individuals responded to the survey; 97% (n = 849) reported a RA diagnosis. The majority were female (87%, n = 757), white (93%, n = 811) and between 61-80 years of age (58%, n = 512). Approximately 75% reported being at least somewhat satisfied with their current treatments, while 18% (n = 158) were somewhat dissatisfied and 6% (n = 54) not satisfied. When asked about the frequency of flares per month while on treatment, only 12% (n = 101) reported no flares monthly, while 38% (n = 328) reported fewer than one flare per month and 51% (n = 445) experienced one or more flares per month. Regarding the availability of treatment options, 34% (n = 296) indicated more options would be beneficial, and 16% (n = 141) said additional options were urgently needed. Most respondents (74%, n = 649) reported currently taking disease-modifying antirheumatic drugs (DMARDs). In addition, 41% (n = 355) reported currently being on biologic DMARDs. Only one in three (33%, n = 287) reported having used more than one biologic or JAK inhibitor. Respondents also reported substantial impacts of RA on their daily life. The most frequently cited burdens included sleep disruption and fatigue (77%, n = 669), unpredictable flares (67%, n = 586), pain intensity (61%, n = 537) and impaired mobility/function (59%, n = 514). Psychosocial concerns were also prevalent, with 42% (n = 396) citing lack of support and 41% (n = 355) identifying psychological stress, depression, or anxiety. Conclusion This large national survey illustrates that, although treatment has advanced, pressing unmet needs remain for RA patients. Despite relatively high treatment satisfaction, half of respondents experienced at least one flare per month, suggesting satisfaction with treatment may not correlate with optimal disease control and indicating low expectations of treatment effectiveness. Moreover, half of respondents expressed a desire for additional therapeutic options, underscoring the importance of continued innovation in RA treatment and indicating the need for therapies that more effectively address flares, fatigue and quality of life impacts. Disclosure A. Bosworth: None. S. Matthews: None. B. Aselage: None. M. da Silva: None.